This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety as Assessed by Adverse Event Reporting
Timeframe: Day 1 through Day 56
Safety as Assessed by Slit-lamp Biomicroscopy
Timeframe: Screening through Day 56
Safety as Assessed by Best-Corrected Distance Visual Acuity
Timeframe: Screening through Day 56